Skip to main content

Table 2 Results of the univariate and multivariate analyses of prognostic factors for OS

From: Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

 

Univariate analysis

Multivariate analysis

Characteristic

MST (mos)

5-yr OS (%)

p-value

HR

95 % CI

p-value

Gender

  

0.431

   

 Male

23

27.4

    

 Female

28

24.5

    

Age

  

0.834

   

  < 60 years

24

26.5

    

  ≥ 60 years

21

27.6

    

Weight loss

  

0.292

1.01

0.61–1.66

0.977

  < 5 %

24

28.7

    

  ≥ 5 %

24

20.2

    

Smoking index

  

0.399

   

  ≤ 400

26

26.5

    

  > 400

20

27.4

    

Pretreatment hemoglobin

  

0.580

   

  < 120 g/L

35

-

    

  ≥ 120 g/L

24

26.8

    

Pretreatment KPS

  

0.096

0.68

0.34–1.37

0.285

  < 80

16

9.1

    

  ≥ 80

24

28.0

    

Stage

  

0.303

   

 IIIa

27

31.1

    

 IIIb

23

24.9

    

Histology subtype

  

0.848

   

 SCC

24

28.0

    

 Non-SCC

24

25.1

    

Pretreatment CEA

  

0.076

0.67

0.45–0.99

0.047

  < 5 ng/ml

27

30.9

    

  ≥ 5 ng/ml

23

18.3

    

Radiotherapy technique

  

0.128

1.09

0.66–1.79

0.743

 3D-CRT

18

16.2

    

 IMRT

25

30.1

    

Radiotherapy dose

  

0.014

0.66

0.42–1.04

0.071

  ≥ 60 Gy

25

29.5

    

  < 60 Gy

19

14.9

    

Concurrent chemotherapy

      

 EP

27

29.8

0.365

   

 PC

19

24.0

    

 Others

25

-

    

Treatment modality

  

.012

0.61

0.42–0.88

0.008

 CRT + CCT

27

30.4

    

 CRT

16

22.5

    

Response

  

0.035

0.62

0.40–0.97

0.036

 CR + PR

24

29.7

    

 SD

21

10.6

   Â